NYSE:IKT Inhibikase Therapeutics (IKT) Stock Price, News & Analysis → Secret energy grid to power millions of homes (From Porter & Company) (Ad) Free IKT Stock Alerts $1.69 +0.03 (+1.81%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$1.61▼$1.7050-Day Range$1.26▼$2.2552-Week Range$0.79▼$4.26Volume13,441 shsAverage Volume108,239 shsMarket Capitalization$10.95 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Inhibikase Therapeutics alerts: Email Address Inhibikase Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,260.9% Upside$23.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.87) to ($1.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.40 out of 5 starsMedical Sector681st out of 905 stocksBiological Products, Except Diagnostic Industry112th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingInhibikase Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInhibikase Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Inhibikase Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IKT. Previous Next 0.0 Dividend Strength Dividend YieldInhibikase Therapeutics does not currently pay a dividend.Dividend GrowthInhibikase Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IKT. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Inhibikase Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for IKT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.00% of the stock of Inhibikase Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.81% of the stock of Inhibikase Therapeutics is held by institutions.Read more about Inhibikase Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($1.87) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibikase Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibikase Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibikase Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Inhibikase Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAfter Conviction, More Bad News for TrumpAs a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown.Click here to see the details because this coming election meltdown could trigger… About Inhibikase Therapeutics Stock (NYSE:IKT)Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Read More IKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IKT Stock News HeadlinesJune 5 at 8:05 AM | globenewswire.comInhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development ProgramsMay 21, 2024 | finance.yahoo.comInhibikase Therapeutics First Quarter 2024 Earnings: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)May 20, 2024 | globenewswire.comInhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionMay 19, 2024 | msn.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Call TranscriptMay 18, 2024 | investing.comEarnings call: Inhibikase Therapeutics reports on drug trials progressMay 16, 2024 | msn.comIKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024May 15, 2024 | globenewswire.comInhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityMay 15, 2024 | globenewswire.comInhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementMay 9, 2024 | globenewswire.comInhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionApril 22, 2024 | msn.comLexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare moversApril 20, 2024 | investing.comInhibikase Therapeutics progresses in Parkinson's disease trialsApril 18, 2024 | globenewswire.comInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsApril 3, 2024 | markets.businessinsider.comInhibikase Announces Pre-IND Meeting For IkT-001Pro - Quick FactsApril 3, 2024 | globenewswire.comInhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionApril 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory ProgressApril 2, 2024 | finance.yahoo.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comInhibikase Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 29, 2024 | finance.yahoo.comQ4 2023 Inhibikase Therapeutics Inc Earnings CallMarch 27, 2024 | globenewswire.comInhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityMarch 7, 2024 | finance.yahoo.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 6, 2024 | markets.businessinsider.comBuy Rating Backed by Promising Developments and Regulatory Confidence in Inhibikase’s PipelineMarch 5, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To KnowFebruary 28, 2024 | globenewswire.comInhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001ProSee More Headlines Receive IKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/07/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:IKT CUSIPN/A CIK1750149 Webwww.inhibikase.com Phone678-392-3419FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$23.00 Low Stock Price Target$23.00 Potential Upside/Downside+1,260.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,030,000.00 Net Margins-5,886.15% Pretax Margin-9,796.43% Return on Equity-147.03% Return on Assets-116.72% Debt Debt-to-Equity RatioN/A Current Ratio2.55 Quick Ratio2.55 Sales & Book Value Annual Sales$260,000.00 Price / Sales42.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book0.95Miscellaneous Outstanding Shares6,480,000Free Float5,441,000Market Cap$10.95 million OptionableNot Optionable Beta1.41 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Milton H. Werner Ph.D. (Age 60)CEO, President & Director Comp: $697.96kDr. Roger RushHead of Preclinical ResearchDr. Surendra SinghHead of Chemistry, Manufacturing & ControlsDr. Charles Warren Olanow B.Sc.F.R.C.P.C., M.D., CEO of Clintrex Research Corporation & Member of Scientific Advisory BoardDan WilliamsControllerKey CompetitorsAligos TherapeuticsNASDAQ:ALGSOKYO PharmaNASDAQ:OKYOAchilles TherapeuticsNASDAQ:ACHLCyclo TherapeuticsNASDAQ:CYTHQuince TherapeuticsNASDAQ:QNCXView All Competitors IKT Stock Analysis - Frequently Asked Questions Should I buy or sell Inhibikase Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inhibikase Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IKT shares. View IKT analyst ratings or view top-rated stocks. What is Inhibikase Therapeutics' stock price target for 2024? 1 analysts have issued 1-year price targets for Inhibikase Therapeutics' shares. Their IKT share price targets range from $23.00 to $23.00. On average, they expect the company's share price to reach $23.00 in the next year. This suggests a possible upside of 1,260.9% from the stock's current price. View analysts price targets for IKT or view top-rated stocks among Wall Street analysts. How have IKT shares performed in 2024? Inhibikase Therapeutics' stock was trading at $1.27 on January 1st, 2024. Since then, IKT shares have increased by 33.1% and is now trading at $1.69. View the best growth stocks for 2024 here. When is Inhibikase Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our IKT earnings forecast. How were Inhibikase Therapeutics' earnings last quarter? Inhibikase Therapeutics, Inc. (NYSE:IKT) released its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.06. Inhibikase Therapeutics had a negative net margin of 5,886.15% and a negative trailing twelve-month return on equity of 147.03%. When did Inhibikase Therapeutics' stock split? Inhibikase Therapeutics's stock reverse split on the morning of Friday, June 30th 2023. The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Inhibikase Therapeutics IPO? Inhibikase Therapeutics (IKT) raised $15 million in an IPO on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of Inhibikase Therapeutics? Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:IKT) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.